What is GeNO?
GeNO LLC operates at the intersection of advanced chemistry and medical device engineering. The company is primarily recognized for its GeNOsyl drug delivery technology, which represents a significant departure from conventional nitric oxide administration methods. By chemically generating nitric oxide from nitrogen dioxide, the platform effectively mitigates the risk of nitrogen dioxide co-delivery, a persistent challenge in traditional systems. This precision-engineered solution is designed for both acute hospital environments and outpatient settings, utilizing portable and wearable controllers to ensure consistent therapeutic delivery. With active Investigational New Drug Applications, GeNO is currently validating its technology for diagnostic use in right heart catheterization and broader therapeutic applications for pulmonary arterial hypertension, positioning itself as a high-authority player in the respiratory medicine sector.
How much funding has GeNO raised?
GeNO has raised a total of $54.8M across 4 funding rounds:
Private Equity
$2.1M
Private Equity
$8M
Private Equity
$14.7M
Private Equity
$29.9M
Private Equity (2009): $2.1M, investors not publicly disclosed
Private Equity (2011): $8M, investors not publicly disclosed
Private Equity (2013): $14.7M, investors not publicly disclosed
Private Equity (2017): $29.9M, investors not publicly disclosed
Key Investors in GeNO
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for GeNO?
With the support of its recent capital injection, GeNO is well-positioned to accelerate its clinical development pipeline and expand the reach of its GeNOsyl platform. The company's strategic focus remains on transitioning its proprietary technology from the investigational phase to broader clinical adoption. Future milestones will likely involve the completion of ongoing clinical studies and the potential commercialization of its acute care delivery systems. As the company scales, its ability to maintain rigorous chemical precision while simplifying clinical workflows will be the primary driver of its competitive advantage in the global biopharmaceutical market. Investors and industry stakeholders are closely monitoring the company's progress as it seeks to redefine the standard of care for patients suffering from complex pulmonary and cardiac conditions.
See full GeNO company page
